{"result": {"id": "ad4ce092-cb35-43e0-8b2b-fa3d4b9c2728", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>GUOJ<|>PERSON<|>GuoJ is an author of a meta-analysis and systematic review on the relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD\")\n##\n(\"entity\"<|>WU J<|>PERSON<|>Wu J is an author of a study on the correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD\")\n##\n(\"entity\"<|>YE Y<|>PERSON<|>Ye Y is a co-author of a study on the correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD\")\n##\n(\"entity\"<|>LI C<|>PERSON<|>Li C is a co-author of a study on the correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD\")\n##\n(\"entity\"<|>LIPSON DA<|>PERSON<|>Lipson DA is an author of a study on the reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease\")\n##\n(\"entity\"<|>CRIM C<|>PERSON<|>Crim C is a co-author of a study on the reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease\")\n##\n(\"entity\"<|>CRINER GJ<|>PERSON<|>Criner GJ is a co-author of a study on the reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease\")\n##\n(\"entity\"<|>MARTINEZ FJ<|>PERSON<|>Martinez FJ is an author of a study on the reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease\")\n##\n(\"entity\"<|>RABE KF<|>PERSON<|>Rabe KF is a co-author of a study on the reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease\")\n##\n(\"entity\"<|>FERGUSON GT<|>PERSON<|>Ferguson GT is a co-author of a study on the reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease\")\n##\n(\"entity\"<|>PRISANT LM<|>PERSON<|>Prisant LM is an author of a study on hyperthyroidism as a secondary cause of isolated systolic hypertension\")\n##\n(\"entity\"<|>GUJRAL JS<|>PERSON<|>Gujral JS is a co-author of a study on hyperthyroidism as a secondary cause of isolated systolic hypertension\")\n##\n(\"entity\"<|>MULLOY AL<|>PERSON<|>Mulloy AL is a co-author of a study on hyperthyroidism as a secondary cause of isolated systolic hypertension\")\n##\n(\"entity\"<|>RIVAS AM<|>PERSON<|>Rivas AM is an author of a study on hypertension and hyperthyroidism: association and pathogenesis\")\n##\n(\"entity\"<|>PENA C<|>PERSON<|>Pena C is a co-author of a study on hypertension and hyperthyroidism: association and pathogenesis\")\n##\n(\"entity\"<|>KOPEL J<|>PERSON<|>Kopel J is a co-author of a study on hypertension and hyperthyroidism: association and pathogenesis\")\n##\n(\"entity\"<|>TSELIOS K<|>PERSON<|>Tselios K is an author of a study on whether current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients\")\n##\n(\"entity\"<|>KOUMARAS C<|>PERSON<|>Koumaras C is a co-author of a study on whether current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients\")\n##\n(\"entity\"<|>UROWITZ MB<|>PERSON<|>Urowitz MB is a co-author of a study on whether current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients\")\n##\n(\"entity\"<|>DROSOS GC<|>PERSON<|>Drosos GC is an author of EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome\")\n##\n(\"entity\"<|>VEDDER D<|>PERSON<|>Vedder D is a co-author of EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome\")\n##\n(\"entity\"<|>HOUBEN E<|>PERSON<|>Houben E is a co-author of EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome\")\n##\n(\"entity\"<|>MUNGUIA-REALPOZO P<|>PERSON<|>Munguia-Realpozo P is an author of a study on systemic lupus erythematosus and hypertension\")\n##\n(\"entity\"<|>MENDOZA-PINTO C<|>PERSON<|>Mendoza-Pinto C is a co-author of a study on systemic lupus erythematosus and hypertension\")\n##\n(\"entity\"<|>SIERRA BENITO C<|>PERSON<|>Sierra Benito C is a co-author of a study on systemic lupus erythematosus and hypertension\")\n##\n(\"entity\"<|>HAN C<|>PERSON<|>Han C is an author of a study on cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis\")\n##\n(\"entity\"<|>ROBINSON DW<|>PERSON<|>Robinson DW is a co-author of a study on cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis\")\n##\n(\"entity\"<|>HACKETT MV<|>PERSON<|>Hackett MV is a co-author of a study on cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis\")\n##\n(\"entity\"<|>UMEMURA S<|>PERSON<|>Umemura S is an author of The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)\")\n##\n(\"entity\"<|>ARIMA H<|>PERSON<|>Arima H is a co-author of The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)\")\n##\n(\"entity\"<|>ARIMA S<|>PERSON<|>Arima S is a co-author of The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)\")\n##\n(\"entity\"<|>SESSLER DI<|>PERSON<|>Sessler DI is an author of a study on anesthesia and perioperative care\")\n##\n(\"entity\"<|>BLOOMSTONE JA<|>PERSON<|>Bloomstone JA is a co-author of a study on anesthesia and perioperative care\")\n##\n(\"entity\"<|>JAPANESE SOCIETY OF HYPERTENSION<|>ORGANIZATION<|>The Japanese Society of Hypertension is an organization that provides guidelines for the management of hypertension\")\n##\n(\"entity\"<|>EULAR<|>ORGANIZATION<|>EULAR is an organization that provides recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases\")\n##\n(\"entity\"<|>CHINESE SOCIETY OF CARDIOLOGY<|>ORGANIZATION<|>The Chinese Society of Cardiology is an organization that provides guidelines for the management of hypertension\")\n##\n(\"entity\"<|>CHINESE SOCIETY OF ANESTHESIOLOGY<|>ORGANIZATION<|>The Chinese Society of Anesthesiology is an organization that provides guidelines for the management of anesthesia and perioperative care\")\n##\n(\"relationship\"<|>GUOJ<|>WU J<|>Both are authors of studies on the relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD<|>5)\n##\n(\"relationship\"<|>WU J<|>YE Y<|>Both are co-authors of a study on the correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD<|>8)\n##\n(\"relationship\"<|>WU J<|>LI C<|>Both are co-authors of a study on the correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD<|>8)\n##\n(\"relationship\"<|>LIPSON DA<|>CRIM C<|>Both are co-authors of a study on the reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease<|>8)\n##\n(\"relationship\"<|>LIPSON DA<|>CRINER GJ<|>Both are co-authors of a study on the reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease<|>8)\n##\n(\"relationship\"<|>MARTINEZ FJ<|>RABE KF<|>Both are co-authors of a study on the reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease<|>8)\n##\n(\"relationship\"<|>MARTINEZ FJ<|>FERGUSON GT<|>Both are co-authors of a study on the reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease<|>8)\n##\n(\"relationship\"<|>PRISANT LM<|>GUJRAL JS<|>Both are co-authors of a study on hyperthyroidism as a secondary cause of isolated systolic hypertension<|>8)\n##\n(\"relationship\"<|>PRISANT LM<|>MULLOY AL<|>Both are co-authors of a study on hyperthyroidism as a secondary cause of isolated systolic hypertension<|>8)\n##\n(\"relationship\"<|>RIVAS AM<|>PENA C<|>Both are co-authors of a study on hypertension and hyperthyroidism: association and pathogenesis<|>8)\n##\n(\"relationship\"<|>RIVAS AM<|>KOPEL J<|>Both are co-authors of a study on hypertension and hyperthyroidism: association and pathogenesis<|>8)\n##\n(\"relationship\"<|>TSELIOS K<|>KOUMARAS C<|>Both are co-authors of a study on whether current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients<|>8)\n##\n(\"relationship\"<|>TSELIOS K<|>UROWITZ MB<|>Both are co-authors of a study on whether current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients<|>8)\n##\n(\"relationship\"<|>DROSOS GC<|>VEDDER D<|>Both are co-authors of EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome<|>8)\n##\n(\"relationship\"<|>DROSOS GC<|>HOUBEN E<|>Both are co-authors of EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome<|>8)\n##\n(\"relationship\"<|>MUNGUIA-REALPOZO P<|>MENDOZA-PINTO C<|>Both are co-authors of a study on systemic lupus erythematosus and hypertension<|>8)\n##\n(\"relationship\"<|>MUNGUIA-REALPOZO P<|>SIERRA BENITO C<|>Both are co-authors of a study on systemic lupus erythematosus and hypertension<|>8)\n##\n(\"relationship\"<|>HAN C<|>ROBINSON DW<|>Both are co-authors of a study on cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis<|>8)\n##\n(\"relationship\"<|>HAN C<|>HACKETT MV<|>Both are co-authors of a study on cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis<|>8)\n##\n(\"relationship\"<|>UMEMURA S<|>ARIMA H<|>Both are co-authors of The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)<|>8)\n##\n(\"relationship\"<|>UMEMURA S<|>ARIMA S<|>Both are co-authors of The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)<|>8)\n##\n(\"relationship\"<|>SESSLER DI<|>BLOOMSTONE JA<|>Both are co-authors of a study on anesthesia and perioperative care<|>8)\n##\n(\"relationship\"<|>JAPANESE SOCIETY OF HYPERTENSION<|>UMEMURA S<|>Umemura S is an author of The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)<|>5)\n##\n(\"relationship\"<|>EULAR<|>DROSOS GC<|>Drosos GC is an author of EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome<|>5)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559043, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 3067, "prompt_tokens": 2808, "total_tokens": 5875, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1016}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: GuoJ, etal. Relationship ofinhaled long-act- ingbronchodilatorswithcardiovascularoutcomesamongpatients with stableCOPD: a meta-analysis and systematic review of43 randomized trials[J]. IntJ Chron ObstructPulmonDis,2019,4:  799-808.\n[648]  Wu J,  Ye Y, LiC, et al.  Correlation of inhaled long-acting bronchodilatorswith adversecardiovascularoutcomesinpatients withstableCOPD: aBayesiannetworkmeta-analysisofrandom- ized controlledtrials[J]. J CardiovascPharmacol, 2019, 74(3) :  255-265.\n[649]  LipsonDA, CrimC, CrinerGJ, etal. Reductioninall-causemortal- ity with fluticasone furoate/umeclidinium/vilanterolin patients with chronicobstructivepulmonarydisease[J]. Am JRespirCrit CareMed,2020,201(12) :1508-1516.\n[650]  MartinezFJ, RabeKF, Ferguson GT, etal. Reduced all-cause mortalityin theETHOS trialofbudesonide/glycopyrrolate/for- moterolfor chronic obstructive pulmonary disease.  A random- ized, double-blind, multicenter, parallel-group study[J]. Am J RespirCritCareMed,2021,203(5) :553-564.\n[651]  Prisant LM, GujralJS, MulloyAL.  Hyperthyroidism: a sec- ondary causeofisolated systolichypertension[J]. J Clin Hyper- tens(Greenwich) ,2006,8(8) :596-599.\n[652]  RivasAM, PenaC, KopelJ, etal.  Hypertensionandhyperthy- roidism: association and pathogenesis[J]. Am JMed Sci, 2021,  361(1) :3-7.\n\n\n[653]  TseliosK, KoumarasC, UrowitzMB, etal. Docurrentarterial hypertension treatment guidelines apply to systemic lupus ery- thematosus patients?  A critical appraisal[J]. Semin Arthritis Rheum,2014,43(4) :521-525.\n[654]  DrososGC, VedderD, HoubenE, etal. EULAR recommenda- tionsforcardiovascularrisk managementin rheumaticand mus- culoskeletal diseases,  including systemic lupus erythematosus and antiphospholipid syndrome[J]. Ann Rheum Dis, 2022, 81\n(6) :768-779.\n[655]  Munguia-RealpozoP, Mendoza-Pinto C, SierraBenito C, etal.  Systemiclupuserythematosusand hypertension[J]. Autoimmun Rev,2019,18(10) :102371.\n[656]  Han C, Robinson DW , Jr, HackettMV, etal.  Cardiovascular disease and risk factors in patients with rheumatoid arthritis,  psoriaticarthritis, and ankylosing spondylitis[J]. J Rheumatol,  2006,33(11) :2167-2172.\n[657]  邹和建 ,朱小霞 ,戴生明 ,等.  系统性硬化病诊疗规范[J]. 中华内 科杂志 ,2022,61(8) :874-882.\n[658]  大动脉炎相关高血压诊治多学科共识中国专家组.  中国大动脉 炎相关高血压诊治多学科专家共识[J]. 中华风湿 病 学 杂 志 , 2021,25(5) :289-295,C5-1.\n[659]  陈源源.  围手术期高血压的管理策略[J]. 中 华 高 血 压 杂 志 , 2017,25(8) :786-789.\n[660]  中国心胸血管麻醉学会非心脏手术麻醉分会.  心脏病患者非心 脏手术围麻醉期中国专家临床管理共识(2020) [J]. 麻醉安全与 质控 ,2021,5(2) :63-77.\n[661]  UmemuraS, ArimaH, ArimaS, etal. TheJapaneseSocietyof Hypertension guidelines for the management of hypertension (JSH 2019)[J]. HypertensRes,2019,42(9) :1235-1481.\n[662]  吴军 ,许迪.  非心脏外科手术围术期高血压的评估与处理[J]. 临 床内科杂志 ,2022,39(1) :8-10.\n[663]  Sessler DI, Bloomstone JA,\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_60f11ddbf3e2602e1d8e20217521bd8cbfcc4343addb6cd515170acfde8a0665_v2"}